Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and Graft-versus-host Disease in Allogeneic Hematopoietic Cell Transplantation for High-risk Hematologic Malignancies
Status: Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 22 Apr 2019
Price : $35 *
At a glance
- Drugs Carfilzomib (Primary) ; Busulfan; Fludarabine; Melphalan; Methotrexate; Tacrolimus
- Indications Graft-versus-host disease
- Focus Therapeutic Use
- 17 Apr 2019 Planned End Date changed from 1 Mar 2019 to 1 Oct 2020.
- 31 May 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Mar 2019.
- 31 May 2018 Status changed from recruiting to active, no longer recruiting.